JP7680967B2 - Pd-1に対する抗体およびその使用方法 - Google Patents

Pd-1に対する抗体およびその使用方法 Download PDF

Info

Publication number
JP7680967B2
JP7680967B2 JP2021573797A JP2021573797A JP7680967B2 JP 7680967 B2 JP7680967 B2 JP 7680967B2 JP 2021573797 A JP2021573797 A JP 2021573797A JP 2021573797 A JP2021573797 A JP 2021573797A JP 7680967 B2 JP7680967 B2 JP 7680967B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021573797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536370A (ja
JP2022536370A5 (cg-RX-API-DMAC7.html
Inventor
ウェイン エイ. マラスコ
マシュー チャン
クアン カレン チュー
Original Assignee
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド
Publication of JP2022536370A publication Critical patent/JP2022536370A/ja
Publication of JP2022536370A5 publication Critical patent/JP2022536370A5/ja
Priority to JP2025078346A priority Critical patent/JP2025121996A/ja
Application granted granted Critical
Publication of JP7680967B2 publication Critical patent/JP7680967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021573797A 2019-06-14 2020-06-15 Pd-1に対する抗体およびその使用方法 Active JP7680967B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025078346A JP2025121996A (ja) 2019-06-14 2025-05-09 Pd-1に対する抗体およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861643P 2019-06-14 2019-06-14
US62/861,643 2019-06-14
PCT/US2020/037781 WO2020252471A1 (en) 2019-06-14 2020-06-15 Antibodies against pd-1 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025078346A Division JP2025121996A (ja) 2019-06-14 2025-05-09 Pd-1に対する抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2022536370A JP2022536370A (ja) 2022-08-15
JP2022536370A5 JP2022536370A5 (cg-RX-API-DMAC7.html) 2023-06-21
JP7680967B2 true JP7680967B2 (ja) 2025-05-21

Family

ID=73781315

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573797A Active JP7680967B2 (ja) 2019-06-14 2020-06-15 Pd-1に対する抗体およびその使用方法
JP2025078346A Pending JP2025121996A (ja) 2019-06-14 2025-05-09 Pd-1に対する抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025078346A Pending JP2025121996A (ja) 2019-06-14 2025-05-09 Pd-1に対する抗体およびその使用方法

Country Status (6)

Country Link
US (1) US20220275088A1 (cg-RX-API-DMAC7.html)
EP (1) EP3982997A4 (cg-RX-API-DMAC7.html)
JP (2) JP7680967B2 (cg-RX-API-DMAC7.html)
AU (1) AU2020290971B2 (cg-RX-API-DMAC7.html)
CA (1) CA3141628A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020252471A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026117664A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Engineered cells and uses thereof for treating cancer
WO2026117666A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Bispecific antibodies for treating cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE537190T1 (de) * 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
WO2010041060A1 (en) * 2008-10-08 2010-04-15 Medimmune Limited Targeted binding agents directed to heparanase and uses thereof 463
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
AR088513A1 (es) * 2011-10-24 2014-06-18 Abbvie Inc Inmunoenlazantes dirigidos contra esclerostina
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
JP6974311B2 (ja) * 2015-06-23 2021-12-01 メモリアル スローン ケタリング キャンサー センター 新規pd−1免疫調節剤
WO2017024515A1 (en) * 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
JP6869987B2 (ja) * 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
RU2656181C1 (ru) * 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
US10759848B2 (en) * 2016-08-12 2020-09-01 Arsanis Biosciences Gmbh Klebsiella pneumoniae O3 specific antibodies
TWI780083B (zh) * 2016-11-18 2022-10-11 丹麥商賽門弗鎮公司 抗pd-1抗體及組成物
EP3609915A1 (en) * 2017-04-12 2020-02-19 Pfizer Inc Antibodies having conditional affinity and methods of use thereof
CN109575139A (zh) * 2017-09-29 2019-04-05 上海药明生物技术有限公司 针对表皮生长因子受体和程序性死亡受体的双特异抗体
JP7649239B2 (ja) * 2018-11-30 2025-03-19 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド キメラ抗原受容体ファクトリおよびその使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
医薬・生活衛生局医薬品審査管理課[online], 審議結果報告書[販売名]キイトルーダ点滴静注20mg、同点滴静注100mg, 2018年11月30日[検索日:2024年5月20日], <https://www.pmda.go.jp/drugs/2019/P20190115001/170050000_22800AMX00696000_A100_1.pdf>

Also Published As

Publication number Publication date
JP2025121996A (ja) 2025-08-20
JP2022536370A (ja) 2022-08-15
EP3982997A4 (en) 2023-09-13
EP3982997A1 (en) 2022-04-20
US20220275088A1 (en) 2022-09-01
AU2020290971B2 (en) 2026-08-13
AU2020290971A1 (en) 2021-12-23
WO2020252471A1 (en) 2020-12-17
CA3141628A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
JP7377590B2 (ja) 抗cd3イプシロン抗体およびそれを使用する方法
EP4706769A2 (en) Anti-cd47 antibodies and methods of use thereof
JP7680968B2 (ja) Pd-1に対する抗体およびその使用方法
JP2024511137A (ja) Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法
JP2024541476A (ja) Ctla-4に対する抗体及びその使用方法
JP2026048871A (ja) Pd-l1に対する抗体およびその使用方法
JP2025121996A (ja) Pd-1に対する抗体およびその使用方法
JP2024512574A (ja) Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法
AU2023362569A1 (en) Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
KR20250108093A (ko) Msln에 대한 항체 및 이의 사용 방법
JP2025527491A (ja) Cldn4に対する抗体及びその使用方法
EP4688842A1 (en) Il-10 receptor antibodies and methods of use thereof
WO2025171401A2 (en) Antibodies against cd99 and methods of use thereof
HK40125012A (en) Antibodies against cldn4 and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230613

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250410

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250509

R150 Certificate of patent or registration of utility model

Ref document number: 7680967

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150